ANDA 218411, held by The J Molner. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 218411 (Lidocaine Hydrochloride), held by The J Molner, was first approved by FDA on Apr 29, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS Lidocaine hydrochloride is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride4% · solution;topical | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters